A citation-based method for searching scientific literature

Niamh Coleman, Alice Harbery, Sara Heuss, Igor Vivanco, Sanjay Popat. Lung Cancer 2022
Times Cited: 5







List of co-cited articles
9 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer.
Jürgen Wolf, Takashi Seto, Ji-Youn Han, Noemi Reguart, Edward B Garon, Harry J M Groen, Daniel S W Tan, Toyoaki Hida, Maja de Jonge, Sergey V Orlov,[...]. N Engl J Med 2020
287
60


Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations.
Paul K Paik, Enriqueta Felip, Remi Veillon, Hiroshi Sakai, Alexis B Cortot, Marina C Garassino, Julien Mazieres, Santiago Viteri, Helene Senellart, Jan Van Meerbeeck,[...]. N Engl J Med 2020
261
40

Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration.
Alexander Drilon, Jeffrey W Clark, Jared Weiss, Sai-Hong Ignatius Ou, D Ross Camidge, Benjamin J Solomon, Gregory A Otterson, Liza C Villaruz, Gregory J Riely, Rebecca S Heist,[...]. Nat Med 2020
159
40

MET-Targeted Therapies and Clinical Outcomes: A Systematic Literature Review.
Yiting Dong, Jiachen Xu, Boyang Sun, Jie Wang, Zhijie Wang. Mol Diagn Ther 2022
5
40

Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study.
Shun Lu, Jian Fang, Xingya Li, Lejie Cao, Jianying Zhou, Qisen Guo, Zongan Liang, Ying Cheng, Liyan Jiang, Nong Yang,[...]. Lancet Respir Med 2021
38
40

c-MET Overexpression as a Poor Predictor of MET Amplifications or Exon 14 Mutations in Lung Sarcomatoid Carcinomas.
Xavier Mignard, Anne-Marie Ruppert, Martine Antoine, Julie Vasseur, Nicolas Girard, Julien Mazières, Denis Moro-Sibilot, Vincent Fallet, Nathalie Rabbe, Françoise Thivolet-Bejui,[...]. J Thorac Oncol 2018
27
40

MET IHC Is a Poor Screen for MET Amplification or MET Exon 14 Mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium.
Robin Guo, Lynne D Berry, Dara L Aisner, Jamie Sheren, Theresa Boyle, Paul A Bunn, Bruce E Johnson, David J Kwiatkowski, Alexander Drilon, Lynette M Sholl,[...]. J Thorac Oncol 2019
61
40


Methods for Population-Adjusted Indirect Comparisons in Health Technology Appraisal.
David M Phillippo, Anthony E Ades, Sofia Dias, Stephen Palmer, Keith R Abrams, Nicky J Welton. Med Decis Making 2018
118
20

Pulmonary Sarcomatoid Carcinoma: An Analysis of the National Cancer Data Base.
Conor E Steuer, Madhusmita Behera, Yuan Liu, Chao Fu, Theresa W Gillespie, Nabil F Saba, Dong M Shin, Rathi N Pillai, Suchita Pakkala, Taofeek K Owonikoko,[...]. Clin Lung Cancer 2017
41
20

Pulmonary sarcomatoid carcinoma: University of Cincinnati experience.
Nagla Abdel Karim, James Schuster, Ihab Eldessouki, Ola Gaber, Tariq Namad, Jiang Wang, Changchun Xie, John C Morris. Oncotarget 2017
32
20

Therapeutic strategies in METex14 skipping mutated non-small cell lung cancer.
Leylah M Drusbosky, Richa Dawar, Estelamari Rodriguez, Chukwuemeka V Ikpeazu. J Hematol Oncol 2021
9
20

MEK inhibitors for the treatment of non-small cell lung cancer.
Jing Han, Yang Liu, Sen Yang, Xuan Wu, Hongle Li, Qiming Wang. J Hematol Oncol 2021
49
20

Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research.
James E Signorovitch, Vanja Sikirica, M Haim Erder, Jipan Xie, Mei Lu, Paul S Hodgkins, Keith A Betts, Eric Q Wu. Value Health 2012
179
20

Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves.
Patricia Guyot, A E Ades, Mario J N M Ouwens, Nicky J Welton. BMC Med Res Methodol 2012
996
20

Matching-adjusted indirect comparison: entrectinib versus crizotinib in ROS1 fusion-positive non-small cell lung cancer.
Paula Chu, Miranta Antoniou, Mohit K Bhutani, Amine Aziez, Monica Daigl. J Comp Eff Res 2020
5
20

Current and future treatment options for MET exon 14 skipping alterations in non-small cell lung cancer.
Lingzhi Hong, Jianjun Zhang, John V Heymach, Xiuning Le. Ther Adv Med Oncol 2021
18
20

Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
D Planchard, S Popat, K Kerr, S Novello, E F Smit, C Faivre-Finn, T S Mok, M Reck, P E Van Schil, M D Hellmann,[...]. Ann Oncol 2018
750
20

A Matching-Adjusted Indirect Comparison of Pembrolizumab + Chemotherapy vs. Nivolumab + Ipilimumab as First-Line Therapies in Patients with PD-L1 TPS ≥1% Metastatic NSCLC.
Balazs Halmos, Thomas Burke, Chrysostomos Kalyvas, Ralph Insinga, Kristel Vandormael, Andrew Frederickson, Bilal Piperdi. Cancers (Basel) 2020
8
20

Simulation and matching-based approaches for indirect comparison of treatments.
K Jack Ishak, Irina Proskorovsky, Agnes Benedict. Pharmacoeconomics 2015
41
20

Pembrolizumab+chemotherapy versus atezolizumab+chemotherapy+/-bevacizumab for the first-line treatment of non-squamous NSCLC: A matching-adjusted indirect comparison.
Balazs Halmos, Thomas Burke, Chrysostomos Kalyvas, Kristel Vandormael, Andrew Frederickson, Bilal Piperdi. Lung Cancer 2021
6
20

Savolitinib: First Approval.
Anthony Markham. Drugs 2021
15
20

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.
D Ross Camidge, Yung-Jue Bang, Eunice L Kwak, A John Iafrate, Marileila Varella-Garcia, Stephen B Fox, Gregory J Riely, Benjamin Solomon, Sai-Hong I Ou, Dong-Wan Kim,[...]. Lancet Oncol 2012
944
20

Mechanisms of resistance to EGFR tyrosine kinase inhibitors.
Lihua Huang, Liwu Fu. Acta Pharm Sin B 2015
267
20


An Overview of the Role of Mechanical Stretching in the Progression of Lung Cancer.
Fengying Gong, Yuchao Yang, Liangtao Wen, Congrong Wang, Jingjun Li, Jingxing Dai. Front Cell Dev Biol 2021
2
50

Mechanisms of acquired tumor drug resistance.
Svetlana N Aleksakhina, Aniruddh Kashyap, Evgeny N Imyanitov. Biochim Biophys Acta Rev Cancer 2019
75
20

Short low concentration cisplatin treatment leads to an epithelial mesenchymal transition-like response in DU145 prostate cancer cells.
Yi-Qing Liu, Guo-An Zhang, Bing-Chang Zhang, Yong Wang, Zheng Liu, Yu-Lian Jiao, Ning Liu, Yue-Ran Zhao. Asian Pac J Cancer Prev 2015
11
20


Elevated PDK1 Expression Drives PI3K/AKT/MTOR Signaling Promotes Radiation-Resistant and Dedifferentiated Phenotype of Hepatocellular Carcinoma.
Oluwaseun Adebayo Bamodu, Hang-Lung Chang, Jiann-Ruey Ong, Wei-Hwa Lee, Chi-Tai Yeh, Jo-Ting Tsai. Cells 2020
44
20

Multi-targeted Drug Repurposing Approach for Breast Cancer via Integrated Functional Network Analysis.
Thirukumaran Kandasamy, Plaboni Sen, Siddhartha Sankar Ghosh. Mol Inform 2022
3
33

FOXC2 promotes chemoresistance in nasopharyngeal carcinomas via induction of epithelial mesenchymal transition.
Zhijiao Zhou, Lu Zhang, Bowen Xie, Xiangpu Wang, Xinhui Yang, Nianhua Ding, Jing Zhang, Qingqing Liu, Guolin Tan, Deyun Feng,[...]. Cancer Lett 2015
62
20

6
20

An epigenetic mechanism underlying doxorubicin induced EMT in the human BGC-823 gastric cancer cell.
Rong-Fei Han, Xiang Ji, Xing-Gao Dong, Rui-Jing Xiao, Yan-Ping Liu, Jie Xiong, Qiu-Ping Zhang. Asian Pac J Cancer Prev 2014
18
20


Targeting Farnesoid X receptor (FXR) for developing novel therapeutics against cancer.
Sosmitha Girisa, Sahu Henamayee, Dey Parama, Varsha Rana, Uma Dutta, Ajaikumar B Kunnumakkara. Mol Biomed 2021
11
20

Increased sensitivity of human lung adenocarcinoma cells to cisplatin associated with downregulated contactin-1.
Ruijie Zhang, Wei Yao, Pin Qian, Yingjie Li, Chaowen Jiang, Zhi Ao, Guisheng Qian, Changzheng Wang, Guoming Wu, Jin Li,[...]. Biomed Pharmacother 2015
15
20

Activation of β-catenin signaling is critical for doxorubicin-induced epithelial-mesenchymal transition in BGC-823 gastric cancer cell line.
Rongfei Han, Jie Xiong, Ruijing Xiao, Ehtisham Altaf, Jin Wang, Yanping Liu, Hui Xu, Qianshan Ding, Qiuping Zhang. Tumour Biol 2013
26
20


Epithelial-mesenchymal transition and its transcription factors.
Pallabi Debnath, Rohit Singh Huirem, Paloma Dutta, Santanu Palchaudhuri. Biosci Rep 2022
11
20

Lung cancer and epithelial-mesenchymal transition.
Toshi Menju, Hiroshi Date. Gen Thorac Cardiovasc Surg 2021
5
20

The Multiple Roles of Glucose-6-Phosphate Dehydrogenase in Tumorigenesis and Cancer Chemoresistance.
Jiaqi Song, Huanran Sun, Shuai Zhang, Changliang Shan. Life (Basel) 2022
3
33


The Role of Contactin 1 in Cancers: What We Know So Far.
Yumei Liang, Cui Ma, Fengjuan Li, Guanhua Nie, Haining Zhang. Front Oncol 2020
5
20

Cisplatin treatment of primary and metastatic epithelial ovarian carcinomas generates residual cells with mesenchymal stem cell-like profile.
Ardian Latifi, Khalid Abubaker, Natalie Castrechini, Alister C Ward, Clifford Liongue, Francoise Dobill, Janani Kumar, Erik W Thompson, Michael A Quinn, Jock K Findlay,[...]. J Cell Biochem 2011
183
20

Mechanisms of Primary Membranous Nephropathy.
Yan Gu, Hui Xu, Damu Tang. Biomolecules 2021
11
20

Pharmacological basis and new insights of deguelin concerning its anticancer effects.
Zhu Yue Lin, Qu Zhen Yun, Liu Wu, Tian Wen Zhang, Tang Ze Yao. Pharmacol Res 2021
5
20

A Mixture of Baicalein, Wogonin, and Oroxylin-A Inhibits EMT in the A549 Cell Line via the PI3K/AKT-TWIST1-Glycolysis Pathway.
Hui-Juan Cao, Wei Zhou, Xiao-Le Xian, Shu-Jun Sun, Pei-Jie Ding, Chun-Yu Tian, Fu-Ling Tian, Chun-Hua Jiang, Ting-Ting Fu, Shu Zhao,[...]. Front Pharmacol 2022
4
25

Coumarin Derivatives Exert Anti-Lung Cancer Activity by Inhibition of Epithelial-Mesenchymal Transition and Migration in A549 Cells.
Rodrigo Santos Aquino de Araújo, Julianderson de Oliveira Dos Santos Carmo, Simone Lara de Omena Silva, Camila Radelley Azevedo Costa da Silva, Tayhana Priscila Medeiros Souza, Natália Barbosa de Mélo, Jean-Jacques Bourguignon, Martine Schmitt, Thiago Mendonça de Aquino, Renato Santos Rodarte,[...]. Pharmaceuticals (Basel) 2022
3
33


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.